About 131 I apamistamab (Iomab-B)
- 131I apamistamab (Iomab-B) is currently being studied in the SIERRA clinical trial. It is an investigational drug (not approved by the FDA) that targets bone marrow and blood cancer (leukemia) cells. It is used to help patients get ready for bone marrow transplant (BMT) also known as hematopoietic stem cell transplantation (HSCT). A bone marrow transplant remains an important, potentially curative option in this population.
- 131I apamistamab (Iomab-B) is a targeted therapy being developed for AML, comprised of a monoclonal antibody that is connected to radioactive material (making it a radiolabeled antibody). 131I apamistamab (Iomab-B) delivers radiation preferentially to your bone marrow and spleen, where most leukemia cells are, when compared to other organs such as liver, lungs, kidneys and mucous membranes that can be harmed by too much radiation.
- 131I apamistamab (Iomab-B) was initially developed at the Fred Hutchinson Cancer Research Center in Seattle, WA. Previous studies of 131I BC8 at that institution showed promise, when Iomab-B was used as part of the preparation for a bone marrow transplant.
- 131I apamistamab (Iomab-B) may allow some patients with relapsed or refractory Acute Myeloid Leukemia to get a bone marrow transplant.
